The 778-subject PROGRESS trial tested Qulipta in migraine patients who had been experiencing headache on 15 or more days per month, for at least three months, with AbbVie's drug given as either 60 ...

AbbVie acquired Qulipta in 2020 as part of its $63 billion takeover of Allergan, which also brought in Botox and Ubrelvy. Botox is prescribed for the prevention of headaches in adults diagnosed ...